TLRY Earnings

TLRY reported its earnings on 2026-04-01, showcasing a revenue of 206.73M against an estimate of 205.93M, resulting in a 0.39% surprise. The EPS was -0.24, surpassing the expected -0.14 by -71.43%. The stock experienced a -5.1% price change on the earnings day and a -0.15% change over the next five days, reflecting market reactions to the results.

Following TLRY's earnings announcement on 2026-04-01, the stock price moved by -5.1% on the day of the release. Over the subsequent five days, it saw a -0.15% change. Historically, TLRY's stock price tends to shift by an average of 6.15% in the 10 days leading up to earnings and -1.88% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate TLRY's annual revenue to reach 240.44M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TLRY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TLRY's stock price typically moves by 6.15% in the 10 days before its earnings and -1.88% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 240.44M.

The earnings call summary and Q&A reflect a positive sentiment overall. The company shows strong international growth, particularly in Europe, and is expanding its distribution footprint. The strategic partnerships and product innovations in the beverage and wellness segments are promising. Despite some uncertainties in cost management and market projections, the reaffirmed EBITDA guidance and strategic plans for cannabis rescheduling in the U.S. and international expansion are positive indicators. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.